

## Catalog # 10-3313

## Lenvatinib

CAS# 417716-92-8

4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E7080 Lot # X107623

$$H_2N$$

Lenvatinib is a potent inhibitor of VEGFR2 and R3, IC<sub>50</sub>s=4.0 and 5.2 nM respectively.<sup>1</sup> Also inhibits VEGFR1, FGFR1, PDGFR3b and Kit, IC<sub>50</sub>s=22, 46, 39 and 100 nM respectively.<sup>1</sup> Suppresses lymph node and lung metastasis in human mammary breast tumor model.<sup>2</sup> Suppresses tumor cell migration and invasion.<sup>3</sup> Inhibits angiogenesis.<sup>4</sup>

- 1) Matsui et al. (2008), E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition; Int. J. Cancer, 122 664
- 2) Matsui et al. (2008), Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase; Clin. Cancer Res., **14** 5459
- 3) Glen et al. (2011), E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion; BMC Cancer, **11** 309
- 4) Yamamoto et al. (2014), Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage; Vasc. Cell, **6** 18

## **PHYSICAL DATA**

Molecular Weight: 426.86

Molecular Formula:  $C_{21}H_{19}CIN_4O_4$ Purity: >98% by HPLC

NMR: (Conforms)
DMSO (20 mg/ml)

Solubility: DMSO (20 mg Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.